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S U M M A R Y
Hepatitis B virus (HBV) is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC). Eight
different HBV genotypes have been identiﬁed with distinct geographical distributions. Different
genotyping methods exist including sequencing, INNO-LiPA, restriction fragment polymorphism (RFLP),
multiplex PCR, serotyping, oligonucleotide microarray chips, reverse dot blot, restriction fragment mass
polymorphism (RFMP), invader assay, and real-time PCR. Several investigators have studied the
inﬂuence of HBV genotypes on clinical outcomes in chronic HBV patients. This review describes the
current genotyping techniques, as well as their advantages and limitations. It also presents the clinical
evidence that correlates HBV genotypes to clinical outcomes including disease severity, HCC
development, response to therapy, disease chronicity, transplantation outcomes, and occult infection.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infects nearly two billion people
worldwide.1 Approximately 600,000 deaths occur every year as a
result of the acute and chronic consequences of HBV infection.1
Disease chronicity rates are5% in generally healthy infected adults
and 80–90% in perinatally infected children.2 Chronic HBV affects
nearly 350 million patients worldwide and may further progress to
cirrhosisand/orhepatocellular carcinoma (HCC) in15–40%ofcases.3
Worldwide,HBVaccounts for30%of cirrhotic and50%ofHCCcases.4
The viral genome is a 3.2 kb circular partially duplex DNA
molecule with the circularity maintained by 50 cohesive ends. The
negative DNA strand is responsible for mRNA transcription. The
genome is made exclusively of condensed coding regions with four
overlapping open reading frames (ORFs). The ﬁrst, ORF P, codes for
a terminal protein on the minus strand as well as viral polymerase
(reverse transcriptase, RNase H, and DNA polymerase activity).
ORF C codes for nucleocapsid structural protein as well as HBV e
antigen (HBeAg), which is responsible for immunomodulation and
replication inhibition functions. ORF S/pre-S codes for viral surface
glycoproteins (HBsAg; hepatitis B surface antigen) that bind to cell
receptors and facilitate viral entry. Finally, ORF X codes for a* Corresponding author. Tel.: +20 2 2615 2543; fax: +20 2 2795 7565.
E-mail address: hazzazy@aucegypt.edu (Hassan M.E. Azzazy).
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doi:10.1016/j.ijid.2010.03.020transcriptional transactivator that codes for involved in the
development of HCC4–6 (Figure 1).
Due to the lack of proof-reading activity of DNA- and RNA-
dependent DNA polymerase, mis-incorporations of nucleotides
occur during viral replication. The rate of nucleotide substitution
per site is estimated to be 1.4–3.2  105 per year.7,8 This has led to
the emergence of HBV genotypes and subgenotypes. At least eight
different genotypes (A–H) have been identiﬁed that differ in more
than 8% of the genome, while subgenotypes differ by at least 4%.9
The phylogenetic tree of complete HBV genomes showing the
alignment of the different genotypes has been reviewed else-
where.10 Table 1 shows the updated global distribution of HBV
genotypes/subgenotypes10–22.
2. Common HBV genotyping methods
At least 10 different HBV genotyping methods have been
developed which have variable sensitivity, speciﬁcity, turnaround
time, and cost. A comparison of the 10 different genotyping
techniques is presented in Table 24,9,23–47.
2.1. Sequencing and phylogenetic analysis
The gold standard method for HBV genotyping is whole genome
sequencing followed by phylogenetic analysis.4,23 Although this
technique is highly sensitive and allows the detection of new and
recombinant genotypes, it is expensive, time-consuming, andses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. HBV genome (modiﬁed from Feitelson and Larkin6).
The HBV genome (3.2 kb) is a circular partially duplex DNA molecule with the
circularity maintained by 50 cohesive ends. The genome is made exclusively of
condensed coding regions with four overlapping open reading frames (ORFs),
namely ORF P, C, S/pre-S, and X.4,5
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In order to sensitively detect the mixed genotypes, a greater clone
number (more than 100) needs to be screened, further affecting cost
and time requirements. An alternative towhole genome sequencing
is single gene sequencing.23 The sensitivity of single gene sequenc-
ing depends on the degree of sequence homology as well as the
sequence size.4,23 It is important to note that a commercial direct
sequencing assay kit is available (TRUGENE HBV Genotyping Kit;
SiemensMedical SolutionsDiagnostics, NY,USA).48 This kit is a two-
in-one kit where, in about 8 h, both genotypes and HBV sequence
mutations can be detected in plasma or serum specimens
simultaneously. First, DNA extraction from plasma or serum is
performed, followed by ampliﬁcation of the hepatitis B surfaceTable 1
Global distribution of HBV genotypes and subgenotypes10–22
Genotype Distribution
A Pandemic, but mostly prevalent in the USA and Northwest Eu
B Northern and Southeast Asia
C Asia and Paciﬁc region
D Mediterranean, the Middle East, North America, and India
E Africa and Tunisia
F Central and South America
G France, Germany, and USA
H Central and South America and Mexico
HBV, hepatitis B virus; NA, data not available.antigen (HBsAg) gene (s101–s237) and overlapping polymerase
gene (rt99–rt280) using PCR.48 PCR amplicons are then added into
four CLIPTM sequencing reaction tubes. Bi-directional sequencing
follows using two ﬂuorescently-labeled DNA primers, thus enhanc-
ing process accuracy. The sequence obtained is compared to
reference sequences for genotypes A–H to determine HBV genotype
and to a universal mutation reporting reference sequence for
mutational analysis.48 The detection limit reported by the manu-
facturer is about 2.0 103 HBV DNA copies/ml, which can be
improved if the DNA extraction method is optimized.49,50 When
MagNA Pure LC rather than manual DNA extraction was used
togetherwith the TRUGENEGenotypingKit, an analytical sensitivity
of 200 IU/ml was achieved (1 IU/ml is about 5 copies/ml).50
2.2. INNO-LiPA
This is a reverse hybridization method that has been developed
by Innogenetics and is commercially available as INNO-LiPA. First,
HBV DNA is ampliﬁed by PCR using biotinylated primers
complementary to a conserved sequence in the S/pre-S ORF.51
The ampliﬁed biotinylated PCR products are then hybridized to
probes immobilized onto membrane strips that detect genotype-
speciﬁc differences in the HBV polymerase gene domains B to C.
After washing, alkaline phosphatase (ALP)-labeled streptavidin is
added, followed by substrate (BCIP/NBT chromogen) that gives a
purple/brown precipitate in the presence of ALP.51 This method
can detect both single and mixed genotypes.4 In 2006, Qutub et al.
reported that the analytical sensitivity of a modiﬁed INNO-LiPA
(using a standardized single-round INNO-LiPA and automated
sample processing, and adding uracil N-glycosylase) was 100%,
90%, and only 10% at viral loads of 1000, 100, and 10 IU/ml,
respectively.24 The overall success rate for the detection of all eight
HBV genotypes by this method was 98% using 100 clinical
specimens with the majority having viral titers ranging from
105 to 107 IU/ml . However, it is important to note that genotypes
A–C were the most commonly analyzed samples.24
2.3. Restriction fragment polymorphism (RFLP)
RFLP depends on PCR ampliﬁcation of the S gene (usually),
restriction enzyme digestion, and separation of digested fragmentsSubgenotype Distribution
rope Aa/A1 Asia and Africa
Ae/A2 Europe and USA
Bj/B1 Japan
Ba/B2 China, Taiwan, and Vietnam
B3 Indonesia
B4 Vietnam
B5 Philippines
Ce/C1 East Asia
Cs/C2 South-east Asia
C3 Polynesia, Solomon Islands
C4 Northeast Australia
D1 India, Pakistan, Iran
D2 India, Russia, and the Baltic region
D3 India, Pakistan
D4 Solomon Islands, Oceania
D5 India
NA NA
F1 Central America, Peru, Venezuela
F2 Venezuela
F3 Venezuela
F4 Bolivia
NA NA
NA NA
Table 2
Comparison of common HBV genotyping methods
Genotyping technique Advantages Disadvantages
Sequencing  Gold standard, most reliable as it does not depend
on a small nucleotide or amino acid sequence as
other methods do23
 Less efﬁcient in detecting mixed genotypes23,31
 Can detect new genotypes and recombination
between genotypes23
 Cumbersome (cannot be used in large-scale
studies), expensive, and requires expertise23,31
INNO-LiPA  Easier and cheaper than sequencing23
 Overall success rate for the detection of all eight HBV
genotypes was recently found to be 98%24
 Insensitive for HBV genomes with SNP or
deletions in the sequences to which probes bind4
 Highly speciﬁc31
 Can detect mixed genotypes4,31
 Relatively expensive compared to PCR-based
and serological techniques23
RFLP  Simple and cost-effective method  May give indeterminate results (<6%)39,41,43
 Can be used in large population studies
 Can determine subgenotypes42
 SNP at enzyme restriction sites may affect
method sensitivity23
Multiplex PCR  Rapid, simple, and cost-effective method  Indeterminate samples range from 2.9% to 4.5%9,46
 Can be used in large population studies  SNP at primer site may affect method sensitivity23
 Can determine subgenotypes25,44,45
 Accuracy reported to be 93%26
 Sensitive in detecting mixed genotypes (even if minor
genotype is as low as 10%)26
Serotyping  No PCR required  Indeterminate samples range from 1.4% to 23.4%29,40,47
 Simple and cost-effective  SNP may affect process sensitivity23
 Can be used in large population studies23,27,28
Oligonucleotide microarray chips  Sensitive  More expensive than real-time PCR and sequencing30
 Determines genotype even at titers as low as 2000–5000
copies/ml30,31
 Sensitivity may be affected by SNPs or deletions
in the sequences to which the probes bind
 Superior to sequencing in determining mixed genotypes30
Reverse dot blot  Can detect mixed genotypes32
 High sensitivity
 Sensitivity may be affected by SNPs or deletions
in the sequences to which the probes bind
 Inexpensive, accurate, and rapid
 Detection limit for genotypes B and D were found to be
102–103 and for A, C, and E were 103–104 copies/ml32
RFMP  High sensitivity  SNP at enzyme restriction sites may affect
method sensitivity Can also be used to detect YMDD mutations with higher
sensitivity and lower detection limit (100 copies/ml33)
compared to sequencing and can also detect mutations
even in samples containing wild-type33–35
 Requires the availability of MALDI-TOF mass
spectrometry (bulky, expensive, and requires
trained operators)
Invader assay  Extremely high sensitivity (detection threshold is 10 copies
of HBV DNA/reaction36)
 Sensitivity may be affected by SNPs or deletions
in the sequences to which the probes bind
 Can detect mixed genotypes even if the ratio between the
two is 1000:1036
Real-time PCR  Low cross-contamination  SNP at primer site may affect method sensitivity
 Time saving
 High throughput
 Lower ability to distinguish between genotypes with
close proximity between Tm
37,38
 High sensitivity 37,38
 Superior than sequencing and oligonucleotide microarray chips in
detecting mixed populations30
HBV, hepatitis B virus; MALDI-TOF, matrix-assisted laser desorption/ionization- time-of-ﬂight; PCR, polymerase chain reaction; RFLP, restriction fragment length
polymorphism; RFMP, restriction fragment mass polymorphism; SNP, single nucleotide polymorphisms; Tm, melting temperature; YMDD, tyrosine–methionine–aspartate–
aspartate motif.
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enzymes has been used for RFLP, the choice of which has been
determined according to the different HBV genotype sequences in
GenBank.11 This method has been used to determine genotypes A–
F.52,53 In 2004, Zeng et al. developed a modiﬁed RFLP technique
based on the S gene allowing the detection of HBV genotypes A–
H.54 In this method, two PCR rounds were undertaken prior to
restriction enzyme digestion by ﬁve enzymes, namely StyI, BsrI,
DpnI, HpaII, and EaeI.54 The method was compared with another
RFLP method targeting the pre-S1 region and the results were
concordant in 96.8% (181/187).54 The remaining six samples were
not typeable by the RFLP method based on pre-S1, but were
typeable by the modiﬁed method after cloning and repeated RFLP
analysis as veriﬁed by sequencing.54 Venegas et al. further
modiﬁed this method by performing a single PCR round, followed
by restriction enzyme digestion using Sau3A I, Bsr I, and Hpa II
based on the S gene.55 When the amplicons corresponding to
genotypes A, B, C, D, and F were sequenced and compared with
reference sequences, 99%, 97%, 98%, 97%, and 97% identity was
reported. However the identity for genotypes E, G, and H was less
than 95%.552.4. Multiplex PCR
Naito et al. developed a multiplex nested PCR method for the
detection of genotypes A–F.56 In the ﬁrst round, universal outer
primers were used. For each sample, two second round PCR
reactions were performed using universal inner primers plus
genotype-speciﬁc primers – the ﬁrst reaction to determine
genotypes A–C and the second for genotypes D–F. The products
of the second round were then run on an agarose gel giving
genotype-speciﬁc band sizes. Universal outer primers (used in the
ﬁrst round) and inner primers (used in the second round) were
designed according to the conserved nucleotide sequences
between the pre-S1 and S gene.56 In contrast, genotype-speciﬁc
primers were designed according to the nucleotide sequences in
the region between the pre-S1 and S gene that were conserved
within an HBV genotype but had poor homology with other
genotypes.56 This methodwasmodiﬁed by Kirschberg et al., where
genotypes A–F were successfully detected using genotype-speciﬁc
primer pairs that bind to different regions in the HBV genome in a
single PCR round.57 In 2007, Chen et al. modiﬁed the single round
PCR to determine genotypes A–F in one reaction, as well as to
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another reaction.25Recently, in2008, Liuetal. developedamultiplex
PCR method to identify genotypes A–G (as determined by
phylogenetic analysis) using genotype-speciﬁc primers in two
reactionsbasedon core/surface/polymerase region.26MultiplexPCR
had a higher accuracy (93.2%) compared to the RFLP method (87%)
developed by Mizokami et al.52 For genotypes A–G, the reported
sensitivityof thismethodwas94.1%, 87.3%, 96.8%, 100%, 100%, 100%,
and 100%, the speciﬁcity 92%, 97.5%, 88.9%, 91.7%, 92%, 92%, and 92%
and the lowest copy numberwas 102, 103, 102, 103, 105, 104, and 103
copies/ml, respectively.26 This method can detect mixed genotypes
with sensitivity for detecting minor species as low as 10%.26
2.5. Serological subtyping
In this method, HBV serotypes or subtypes are recognized using
antibodies against HBsAg. Serotypes are made up of a constant ‘‘a’’
determinant, plus two variable, mutually exclusive determinants
d/y and w/r as well as other determinants. This results in nine
serological subtypes, ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4,
adrq+ and adrq. Whenmolecularmethod results werematched to
those obtained with serological assays, it was found that genotype
A corresponded to adw2 (Europe, US, East Africa) and ayw1
(Africa), while B corresponded to adw2 (Asia) and ayw1 (Vietnam).
Genotype Cwasmatchedwith adr and ayr, D with ayw2 and ayw3,
E with ayw4, F with adw4, G with adw2, and H with adw4.10,27,28
Although PCR and sequencing have been used as the standard
methods for genotyping, sequencing is not suitable for large
epidemiological studies and population screening.27,28 In contrast,
serological assays using monoclonal anti-HBs antibodies with
restricted subtype speciﬁcities in an enzyme immunoassay format
are more cost-effective, easy to perform, and have higher
throughput.23,27 Serological assays have also been found to be
superior to molecular methods in typing HBV-PCR-negative
carriers, who constituted 35% of the study population in the study
of Laperche et al.27 However, it has been reported that the rate of
indeterminate samples may reach up to 23.4%.29
2.6. Oligonucleotide microarray chips
Song et al. developed a low density oligonucleotide microarray
that can determine genotypes A–G.58 First, PCR ampliﬁcation of the
pre-S region was performed with subsequent Cy5-dCTP labeling.
The ampliﬁed productswere heat denatured and added to silylated
slides to which genotype-speciﬁc probes are immobilized. Fifteen
probes were designed based on phylogenetic tree analysis and
alignment of 228 pre-S region sequences. Following washing and
drying, ﬂuorescence signals were captured using a scanner. This
method was found to be speciﬁc and was found to be sensitive to
detect both single and mixed genotypes. Total concordance was
achieved with RFLP (pre-S1; 37/37) and sequencing (24/24).58
In 2007,Wang et al. compared oligonucleotidemicroarray chips
to real-time PCR and sequencing.30 They reported that the
oligonucleotide chip detected both genotypes B and C if the
mixture contained 50%, 10%, or even 1% of genotype B. However,
when genotype B was only 0.1%, the method only detected
genotype C. This was superior to sequencing, which detected both
genotypeswhen the concentration of genotype Bwas 50%, but only
genotype C when the concentration was 10%, 1%, or 0.1%.30 Real-
time PCR was, however, more sensitive than both oligonucleotide
chip and sequencing in detecting genotypemixtures. Itmanaged to
detect both genotypes even when genotype Bwas as low as 0.1%.30
The oligonucleotide chip method was found to be superior to both
sequencing and real-time PCR with respect to sensitivity.30 Real-
time PCR and sequencing were only able to determine the
genotype when the titer was higher than 5.20  103 but not whenit was 20  102 copies/ml. In contrast, oligonucleotide chip was
able to determine genotype at all tested dilutions.30 When clinical
samples were tested, 93% (117/126) of the results obtained by the
three methods were concordant.30 In the nine discordant samples,
sequencing only determined the predominant genotype, however
both real-time PCR and oligonucleotide chip determined both
genotypes.30 According to this study, the cost of analyzing a single
sample was 120 Chinese Yuan for oligonucleotide chip, 70 Chinese
Yuan for real-time PCR, and 100 Chinese Yuan for sequencing.30
In 2008, Pas et al. reported the use of a prototype chip and
compared the results with phylogenetic analysis.31 First, PCR was
performed, followed by biotin labeling, fragmenting, purifying, and
hybridizing the amplicons with the chip. Samples were then
stained with streptavidin–phycoerythrin conjugate and examined
using a scanner. The detection limit of the DNA chip was nearly
5000 copies/ml and the sensitivity and speciﬁcity were 97.5% and
97.8%, respectively.31
2.7. Flow-through reverse dot blot (FT-RDB)
Zhang et al. developed a FT-RDB for HBV genotyping based on a
conserved region of the HBV S gene.32 First, PCR was performed
using a 50-biotin labeled reverse primer. PCR amplicons were then
denatured and rapidly cooled by ice prior to hybridization. The PCR
products were then added to a nylon membrane to which
genotype-speciﬁc probes were immobilized. After hybridization,
detection was performed by the addition of streptavidin–
horseradish peroxidase, followed by chromogen 3,3,5,5-tetra-
methylbenzidine (TMB). Any reagent added onto the nylon
membrane was sucked through it using a hybridization machine
that was equipped with a vacuum pump. Concordance between
FT-RDB and sequencing was 96% (97/101). The four discordant
samples were found to be mixed infection by FT-RDB but not by
sequencing. The detection limit for examining genotypes B and D
ranged between 102 and 103 copies/ml, and for A, C, and E ranged
between 103 and 104 copies/ml.32 This method is thus an
inexpensive, accurate, and rapid method for HBV genotyping.32
2.8. Restriction fragment mass polymorphism (RFMP)
Lee et al. utilized RFMP for HBV genotyping based on genotypic
variations in the S gene.59 Similar to RFLP, this method depends on
restriction enzyme digestion of PCR products to produce genotype-
speciﬁc oligonucleotide fragments. The mass of the produced
fragments is then determined using matrix-assisted laser desorp-
tion/ionization–time-of-ﬂight (MALDI-TOF) mass spectrometry.59
Other studies have reported the use of MALDI-TOF mass
spectrometry for determination of YMDD (tyrosine–methionine–
aspartate–aspartate motif) mutations, which are linked to
lamivudine (LAM) drug resistance.33–35 In such studies, the
method was found to be superior to DNA sequencing since it
has a lower detection limit (100 copies/ml33) and can also detect
mutations in samples containing wild type.33–35
2.9. PCR invader assay
Tadokoro et al. developed a PCR invader assay that successfully
determined genotypes/subtypes Ae, Aa, Ba, Bj, and C–H.36 Ampliﬁ-
cation of the core/S region was ﬁrst performed by multiplex PCR.
Thiswas followedbytwo invaderreactions ina384-wellplate.36The
ﬁrst reaction involves the binding of invader oligo as well as
genotype-speciﬁc primary probes (P1 and P2) to the puriﬁed PCR
amplicon.According to theHBVgenotype, cleavageof eitherP1orP2
at their 50 end will occur secondary to the binding of both invader
oligo and primary probes.36 This results in the release of what is
knownas 50 ﬂap. In the second reaction, the released 50 ﬂapproducts
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cleavage and the release of a speciﬁc ﬂuorescent signal.36 The
ﬂuorescence signal produced thus corresponds to theHBV genotype
and can be detected using a ﬂuorescence plate reader. The detection
threshold of thismethod is only 10 copies of HBVDNA/reaction and
this method can detect mixed genotypes even if the ratio between
the two genotypes is 1000:10.36 Concordance between PCR invader
assay and enzyme-linked immunosorbent assay (ELISA) was 98.2%
and between PCR invader assay and INNO-LiPA was 97.1%.36 The
invader assay was proven to provide accurate results in non-
concordant samples as veriﬁed by sequencing.36
2.10. Real-time PCR
Thismethod identiﬁes both the HBV genotype and the HBVDNA
level in serum, which aids in the prediction of therapeutic
outcome.37,38,60 Real-time PCR using SYBR green I (a nucleic acid
dye thatbinds todouble-strandedDNA)orﬂuorescentprobesallows
the detection and quantiﬁcation of HBV DNA, while melting curve
analysis allows the determination of genotypes. Melting tempera-
ture(Tm) valuediffersbetweendifferentgenotypesdependingon the
complementarily betweenprobeand target and/orGCcontentof the
hybridization sequence. 37,38,60 Payungporn et al. reported that the
concordance between melting curve analysis and sequencing was
92.3%, while between RFLP and sequencing was only 90.4%.37 Also,
Liu et al. found that results obtained with Tm analysis provided
accuracyof 92.3%,which exceeded that of RFLP (87%).38Unlike other
methods for genotyping, real-time PCR does not allow for cross-
contamination, is time-saving, has a high throughput, and is highly
sensitive.37,38 The main disadvantage of this method is that it has a
lower ability todistinguishbetweengenotypeswith close proximity
between their Tm values, such as A and C, and thus could not be
applied in certain countries such as North America which include
different genotypes.37 However, this method could be modiﬁed
through use of a stepwise approach, where ﬁrst the genotype is
differentiated into either ACDE or BFG groups, then the exact
genotype is determined within the group.38
3. Clinical implications of HBV genotypes
3.1. Disease severity and HCC development
Disease severity has been found to be inﬂuenced by viral
(including genotype), host, and environmental factors.12,61 The
incidence of HCC is inﬂuenced by HBV genotype, HBV DNA level,
sex, age, pre-core A1896mutation, and basal core promoter T1762/
A1764 mutation.62 This article will only focus on the correlation
between HBV genotypes and disease progression, including the
development of liver cirrhosis and HCC.
3.1.1. GenotypeC is associatedwith faster liver damage thangenotypeB
Most but not all studies have concluded that HBV genotype C
predicts aworse prognosis (including cirrhosis andHCC) compared
to B. Correlation between genotype C and the development of liver
cirrhosis has been reported in numerous studies, including Ding
et al. (Table 3) and You et al. (n = 122 genotyped chronic HBV
Chinese patients; B: 48; C: 69; using reverse dot blot;
p = 0.002).63,64 Many studies (Table 3) have associated genotype
Cwith HCC development.65,66 Interestingly, Chan et al. (n = 86 HCC
patients; sequencing) reported that subgenotype Ce is associated
with higher HCC risk followed by Cs then B (p < 0.0001 for Ce vs. B;
p = 0.02 for Cs vs. B).67 On the other hand, Tseng et al. (n = 242
genotype C HBV carriers; Cs: 23; Ce: 219; subgenotyping
performed by detection of single nucleotide polymorphism at
nucleotide position 1858) reported that the distribution of
genotype C subgenotypes (Ce and Cs) among different diseasestages including inactive carriers, chronic hepatitis patients,
cirrhotic patients, and HCC patients with or without cirrhosis,
was not signiﬁcantly different.68
Several studies have reported that genotype B is associatedwith
less HBeAg positivity and higher HBeAg clearance and serocon-
version compared to C, including the studies of Orito et al. (n = 720
genotyped patients; B: 88; C: 610; RFLP plus sequencing and
phylogenetic analysis; p < 0.01 for HBeAg positivity), Ding et al.
(Table 3), Chu et al. (Table 3), Orito et al. (296 HCC patients; Ba:13;
Bj:22; C:256; RFLP plus sequencing and phylogenetic analysis;
p < 0.01 for Bj vs. C in HBeAg positivity), and You et al. (p = 0.05 for
B vs. C in HBeAg positivity).39,63,64,69,70 These studies further
support the fact that infection with genotype B is associated with
less severe liver damage compared to C.
Sumi et al. reported that HBeAg negativity (p < 0.01) and
seroconversion (p = 0.022) was higher in genotype B than C and
that genotype B is an independent factor associated with HBe
seroconversion (n = 585; genotyped patients; B: 30; C: 224 biopsy
proven chronic liver disease; 74 HCC; ELISA and RFLP).71 Also
advanced ﬁbrosis was signiﬁcantly less common in genotype B
compared to genotype C patients aged 45 years (p = 0.02).
However, the association between genotype C and advanced
ﬁbrosiswas lostwhen patients older than 45 yearswere compared.
Thus they concluded that genotype B patients seem to develop
advanced liver ﬁbrosis slower than genotype C patients, but that
the lifelong risk of advanced ﬁbrosis andHCC development appears
to be similar between genotype B and C patients.71
3.1.2. HCC mean age, metastasis, and recurrence in genotype B and C
patients
Several studies have reported that genotype C is associatedwith
younger HCC mean age compared to B.39,69 Orito et al. (B: 15; C:
100 HCC patients) reported that themean ages of genotype B and C
patients with HCC were 70.1  9.2 years and 55.2  9.7 years,
respectively (p < 0.01).39 Orito et al. (Ba:13; Bj:22; C:256) reported
that subgenotype Bj is associated with HCC in the elderly, while
genotype C is associated with those of a younger age (mean age
difference p < 0.01).69 Interestingly in this study, the mean age for
HCC patients was also signiﬁcantly higher in Bj-infected cases than
the Ba-infected cases (p < 0.01).69
In contrast, other studies have concluded that genotype B is
associatedwithHCC development at a young age and genotype C at
an older age. It was reported that genotype B is linked with HCC
development in young non cirrhotic patients.12 Ni et al. reported
that out of 26 children with HCC resulting from HBV, 74% were
infected with genotype B. 72 Similarly, Yuan et al. (n = 34 HCC
patients; B: 21; C1: 9; C2: 4; ELISA and RFLP) reported that all HCC
patients aged35 years were infected with subgenotype Ba, while
all subgenotype C2 HCC patients were older than 50 years.40
The contradictory ﬁndings reported by the different studies
regarding correlation of genotypes B and C to HCC development
age may be explained by differences in subgenotypes. Further
studies that correlate HBV subgenotypes with HCC mean age are
still required.
HCC recurrence and metastasis were found more common in
genotype C patients compared to B. Huang et al. (69 cases with
recurrence or metastasis) reported that 74% and 41% of patients
infected with genotypes C and B, respectively, suffered from HCC
metastasis or recurrence (p = 0.009).73
3.1.3. Is genotype D more severe than A?
GenotypeD has been reported to bemore severe as compared to
A in some studies. Thakur et al. (130 Indian HBV patients; A: 60; D:
63; RFLP plus gene sequencing) reported that genotype D was
more strongly associated with disease severity (Child’s score B or
C) compared to A (p < 0.05 for genotype D vs. A).74 Lee et al. (475
Table 3
Correlation between HBV genotypes and disease severity and HCC development.
Study Patients and methods Study ﬁndings Conclusions
Ding et al. 200163  n=220 HBV DNA-positive
(China; 95 AS; 46 CH; 35 LC;
44 HCC; B: 38; C: 179)
 27.4%, 17%, 8.6%, and 2.3% of AS, CH, LC, and HCC patients
were infected with genotype B, respectively (p<0.01)
 Genotype C is associated
with HBeAg positivity
 Method: RFLP
 69.5%, 83%, 91.4%, and 97.7% of AS, CH, LC, and HCC patients
were infected with genotype C, respectively (p<0.01)
 Prevalence of genotype C
increases from AS, CH, LC
to HCC, in contrast to
genotype B
 28.9% and 48.6% of patients infected with genotype B and
genotype C were HBeAg-positive, respectively (p<0.05)
Chu et al. 200270  65 genotype B and 102 genotype
C HBeAg-positive patients
 Cumulative rates of HBeAg loss were 8%, 30%, and 50% in
genotype B patients, and 0%, 23%, and 38% in genotype C
patients at years 1, 3, and 5, respectively (p<0.05)
 Genotype B is an independent
factor for HBeAg seroconversion
 Method: INNO-LiPA and
bidirectional automated
sequencing
 Cumulative rates of spontaneous HBeAg seroconversion were
6%, 24%, and 46% in genotype B patients and only 0%, 18%, and
34% in C patients at years 1, 3, and 5, respectively (p<0.05)
 Genotype B is associated
with higher HBeAg loss
 HBeAg seroconversion was 2.3 times higher in genotype B
patients than in genotype C
Sa´nchez-Tapias
et al. 200241
 n=244 (genotyped followed-up
Spanish patients; A:131;
D:94; F:19)
 8%, 4%, and 21% of patients infected with genotypes A, D,
and F experienced hepatic decompensation, respectively
(D vs. F: p=0.02)
 Death resulting from liver
complications was more
common in genotype F
patients than A and D Method: RFLP  2%, 1%, and 5% of patients infected with genotypes A, D,
and F experienced HCC, respectively
 5%, 1%, and 21% of patients infected with genotypes A, D,
and F died due to a liver disease, respectively
(A vs. F: p=0.02; D vs. F: p=0.002)
 55%, 32%, and 26% of A, D, and F achieved sustained
remission, respectively (A vs. F; p=0.01)
Yu et al. 200565  146 HCC genotyped; 286
genotyped non-HCC
 HCC incidencesa were 8/81 and 11/15 in genotype non-C
and C patients (having baseline HBV DNA level of 4.22
log10 copies/ml), respectively
 Genotype C is highly linked
to HCC
 Method: MCA plus sequencing
and phylogenetic analysis
 Genotype C was more linked to HCC compared to other
genotypes (adjusted OR 5.11; 95% CI 3.20–8.18)
Kumar et al. 200575  n=70  ALT levels higher than 1.5 times normal occurred in
81% of genotype A patients but only in 58% of
genotype D (p<0.05)
 Genotype A is more severe
than genotype D
 Method: RFLP and sequencing
and phylogenetic analysis
 HBeAg was positive in 86% of genotype A but only
in 62% of genotype D (p<0.05)
 Negative anti-HBe occurred in 92% of genotype A
but only in 72% of genotype D (p<0.05)
 In patients older than 25 years, 82% of genotype A
patients and 57% of genotype D had cirrhosis (p<0.05)
Toan et al. 200666  86 AS; 92 LC; 84 HCC
(Vietnamese)
 AS: A 33.7%; B 4.6%; C 33.7%; D 5.8%; E 2.3%; F 2.3%;
mixed 17.4%
 Genotype A is highly prevalent
in AS group (p<0.0001), and D
in LC (p<0.0001) Method: modiﬁed RFLP-PCR
assay and sequencing
 LC: A 10.8%; B 8.7%;C 14.1%; D 44.6%; E 2.2%; F 3.3%;
G 3.3%; mixed 13.1%  Genotype C is associated with
HCC (p=0.023) HCC: A 9.5%; B 11.9%; C 34.5%; D 19%; E 4.8%; F 2.4%;
G 8.3%; mixed 9.6%
ALT, alanine transaminase; anti-HBe, antibody to HBV e antigen; AS, asymptomatic; CH, chronic hepatitis; CI, conﬁdence interval; HBeAg, hepatitis B e antigen; HBV, hepatitis
B virus; HCC, hepatocellular carcinoma; LC, liver cirrhosis; MCA, melting curve analysis; OR, odds ratio; PCR, polymerase chain reaction; RFLP, restriction fragment length
polymorphism.
a HCC incidence: measured as the ratio of the number of case patients to the number of control subjects.
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reported that all studied genotype A patients had inactive liver
disease with no HCC.59 Toan et al. (Table 3) also supported the
ﬁnding that genotype D is more associated with liver cirrhosis and
A with asymptomatic carrier.66
In contrast, Kumar et al. (Table 3) reported that genotype A was
more severe than D, being signiﬁcantly more associated with high
alanine transaminase levels, HBeAg positivity, anti-HBe negativity,
and cirrhosis (cirrhosis only signiﬁcant in patients older than 25
years).75 Baig et al. (71 asymptomatic and 14 liver cirrhosis/HCC)
reported a linkage between genotype A and cirrhosis and disease
severity.3 PCR with genotype-speciﬁc primers was used as the sole
genotyping technique in this study.3
Recently, Madan et al. (n = 237 genotyped patients; D: 162; A:
61; ELISA and RFLP) reported that genotypes A and D do not
inﬂuence disease severity and chronicity.76 Long-term studieswith
large homogeneous populations are thus required to understand
the inﬂuence of HBV genotypes A and D on disease severity. Such
studies should implement a common genotyping method veriﬁed
by sequencing.3.1.4. Genotype F is highly associated with severe disease
Genotype F was found to be associated with severe infection
and young HCC development.41,77 Sa´nchez-Tapias et al. (Table 3)
reported that death resulting from liver complications was more
common in genotype F patients than A and D.41 Similarly,
Livingston et al. (n = 1129 non HCC; 47 HCC patients; F:32 HCC;
sequencing) reported a strong link between genotype F and HCC
development (p < 0.001).77 The median age of HCC diagnosis in
genotype F patients was only 22.5 years compared to 60 years for
other genotypes (p = 0.002).77
In summary, genotype C is more associated with rapid
progression to advanced liver ﬁbrosis, higher rate of HCC
development, recurrence and metastasis, higher HBeAg positivity,
and lower HBeAg clearance and seroconversion compared to
genotype B. Genotype D may be more associated with severe
disease and liver cirrhosis compared to A. Finally, genotype F was
found to be more associated with higher mortality rates compared
to other genotypes. Tables 3 and 4 summarize the clinical
implications and the correlation between HBV genotypes and
disease severity.
Table 4
Clinical implications of HBV genotypes to disease severity, response to IFN, disease chronicity, disease transmission, and transplantation outcomes
Clinical
implications
HBV genotype
A B C D
Disease severity  Prevalent in AS66  Less prevalent in the LC
and HCC group compared
to AS63 (Table 3)
 Highly prevalent in the LC
and HCC group compared
to AS63 (Table 3)
 Associated with disease
severity (Child’s scoreb 2
and 3) and LC66,74,a
 HCC recurrence and
metastasis: 41%73
 HCC recurrence and
metastasis: 74%73
Response to IFNc  SR: 47%84,d  Response rates: 39–50%78–80,e  Response rate: 13–17%78–80,e  SR: 23%84,d
 Treatment duration:
4–15 months84
 Treatment duration:
16–24 weeks78–80
 Treatment duration:
16–24 weeks78–80
 Treatment duration:
4–15 months84
 Follow-up period: 12 months
post-treatment84
 Follow-up period: 48–52
weeks78–80
 Follow-up period:
48–52 weeks78–80
 Follow-up period: 12
months post-treatment84
Disease
chronicity
 Some studies report this genotype
in 28.6% of acute vs. 3% of
chronic patients95
 Genotype B was prevalent
in 26–39% of acute and
only 4–11.7% of chronic
patients 97,98
 Found in 84.5% of
chronic vs. 59.5% of
acute hepatitis patients95
 Some studies report
this genotype in 80%
of acute vs. 11% of
chronic patients93 Others report in only 10% of acute
vs. 80% of chronic patients93  Others report 48% of
chronic patients vs.
13.6% of acute patients9,f
Sexual and
vertical
transmissiong
 52% of genotype A patients were
infected through homosexual or
bisexual contact and only
16% by heterosexual102
 67% of genotype B
were infected through
vertical route84
 55% of genotype C were
infected through
vertical route84
 15% of genotype D
patients were infected
through homosexual or
bisexual contact and 42%
by heterosexual conduct102
 45% of genotype D were infected
through vertical route84
Transplant
outcomesh
 Recurrence after
transplantation: 20%110
 Cumulative rates of viral
breakthrough after 3 years: 4%111
 Recurrence after
transplantation: 50–70%110
 Recurrence after
transplantation: 80%110
 Recurrence after: nearly
2.7 months110
 Recurrence is less common
with less severe graft damage
compared to genotype C
 Recurrence after:
nearly 10 months110
 Recurrence after:
nearly 9.1 months110
 ACR: 90%110  ACR: 60%110  ACR: 50%110
 Cumulative rates of viral
breakthrough after
3 years: 21%111
ACR, acute cellular rejection; ALF, acute liver failure; AS, asymptomatic; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IFN, interferon; LC, liver cirrhosis; SR,
sustained responder.
a Other studies (Kumar et al.75 and Baig et al.3) reported that genotype A was more severe than genotype D.
b Child’s score: a scoring system that allows prediction of disease prognosis by measuring bilirubin, serum albumin, international normalized ratio, ascites, and hepatic
encephalopathy.
c Response to nucleoside/nucleotide analogues is suggested not to be signiﬁcantly inﬂuenced by HBV genotypes.92
d The patient population included both HBeAg-positive and negative patients; the table does not include the study of Hou et al.85 which reported that response after
prolonged therapy was independent of HBV genotype.
e HBeAg-positive.
f Patient population: Egyptian pediatric cancer patients.
g Genotypes B and C can be transmitted sexually and genotype A via vertical transmission. Genotype E can also be transmitted through sexual and vertical
routes.84,99,101,107,108
h The study of Ben-Ari et al. 2004112 is not presented in the table; it reports no signiﬁcant difference between genotype prevalence in patients undergoing liver
transplantation and stable patients. Also Girlanda et al.61 reported that genotypes A and D did not signiﬁcantly inﬂuence the outcome of liver transplant.
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The US Food and Drug Administration (FDA) has approved six
drugs for the treatment of HBV infections, namely interferon-alpha
(IFN-a), pegylated IFN-a (PEG-IFN-a), LAM (cytidine analog),
adefovir dipivoxil (ADV; dATP analog that function as chain
terminator), entecavir (20-deoxyguanosine analog that inhibits
polymerase priming activity and chain elongation), and telbivu-
dine (dTTP analog).4 In the coming sections, the inﬂuence of HBV
genotypes on response to therapy will be discussed.
3.2.1. HBeAg-positive genotype B patients are more responsive to IFN
compared to genotype C patients
Many studies have reported that HBeAg-positive genotype B
patientsaremoreresponsiveto IFNcomparedtogenotypeCpatients,
including Chu et al. (Table 5), Kao et al. (n = 58; B:32; C:26; RFLP;
p = 0.045), and Wai et al. (B: 31; C: 42 treated patients; INNO-LiPA
plus direct sequencing; p = 0.03).78–80 Furusyo et al. (n = 158 HBV
Japanese patients; ELISA) reported that genotype C was associated
witha continuationofHBVreplicationevenafterHBeAgclearancebyIFN therapy, indicatingapoorprognosis.81 It is important tonote that
in the study of Luo et al. (n = 261 patients followed up for 3 years;
RFLP and phylogenetic analysis), there was no signiﬁcant difference
in IFN response after a 3-year follow-up period, between genotype C
and recombinant B (recombination with the pre-C/C gene of
genotype C).82 This suggests that different genotype B strains may
have a wide range of different responses to IFN therapy, including
those that are comparable to that of genotype C.
Ma et al. (94 HBeAg-positive patients B: 25; C: 43; D: 16; PCR
microplate hybridization ELISA; 6 months of IFN; 6 months follow
up) reported that genotype Bwas associatedwith a better response
compared to C and D. Only genotype B patients in this study
experienced a complete response.83
3.2.2. Genotype A patients are more responsive to IFN compared to
genotype D patients
Some studies have arrived at the conclusion that genotype A
patients have a better response to IFN compared to those infected
with other genotypes. Importantly, Erhardt et al. (Table 5) reported
that patients with genotype A responded better to therapy
Table 5
Correlation between HBV genotypes and IFN/PEG-IFN response.
Study Patients and methods Study ﬁndings Conclusions
Chu
et al. 200578
 n=202 (Chinese; 126 CH;
76 normal control); B:38;
C: 69; B+C:19
 50%, 13%, and 26% of patients infected with genotypes
B, C, and B+C responded to IFN therapy,
respectively (p<0.005)
 Genotype C patients are more resistant
to IFN therapy compared to B or B+C
 Method: multiplex PCR
 Treatment protocola
Erhardt
et al. 200584
 78 genotype A (61
HBeAg-positive and
17 HBeAg-negative)
 SR-6s were 49% and 26% in HBeAg-positive and
negative patients infected with genotypes A and D,
respectively (p<0.005)
 Genotype A was found to be an
independent positive predictor of
IFN SR (p<0.009)
 66 genotype D (38
HBeAg-positive, 28
HBeAg-negative)
 SR-6s were 46% and 24% in HBeAg-positive patients
infected with genotypes A and D, respectively (p<0.03)
 Method: sequencing
 SR-6s were 59% and 29% in HBeAg-negative patients
infected with genotypes A and D, respectively (p<0.05)
 Treatment protocol:
standard IFN
 SR-12s were 47% and 23% in HBeAg-positive and
negative patients infected with genotypes A and
D, respectively (p<0.002)
 SR-12s were 44% and 24% in HBeAg-positive
patients infected with genotypes A and D,
respectively (p<0.04)
 SR-12s were 59% and 21% in HBeAg-negative
patients infected with genotypes A and D,
respectively (p<0.01)
Janssen
et al. 200586
 n=266 HBeAg-positive
patients (A:90; B: 23; C:39;
D:103 treated patients)
 HBeAg loss was found to be inﬂuenced by HBV
genotypes (p=0.01)
 Genotype A patients were signiﬁcantly
more responsive than D (p=0.01) or C
(p=0.006) and genotype B patients were
slightly more responsive than C Method: INNO-LiPA
 Treatment protocolb
 HBeAg loss was achieved in 47%, 44%, 28%, and 25% of
genotypes A, B, C, and D, 26 weeks following PEG-IFN
with or without lamivudine, therapy, respectively
Bonino
et al. 200790
 518 HBeAg-negative
CHB patients (Asian or
Caucasian; infected with
genotypes A, B, C or D)
 Combined response rates, 24 weeks after end of PEG-IFN
therapy for genotypes B, C, and D patients were 44%,
49%, and 16%, respectively
 HBV genotype was found to be a signiﬁcant
predictor for PEG-IFN with/without LAM
response 24 weeks after treatment (p=0.027)
 Treatment protocolc
 SVR was more linked to genotype C in patients treated with
PEG-IFN with/without LAM compared to D (p<0.001)
 Genotype B (p=0.0033) and C (p<0.0001) achieved
combined response more than D, one year after end of
therapy (PEG-IFN monotherapy or LAM monotherapy or
PEG-IFN plus LAM)
CH, chronic hepatitis; CHB; chronic hepatitis B patients; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; IFN, interferon; LAM, lamivudine; PCR, polymerase chain
reaction; PEG-IFN, pegylated interferon; SR, Sustained response; SR-6, sustained response after 6 months; SR-12, sustained response after 12 months; SVR, Sustained
virological response.
a IFN-a (3 MU) injected subcutaneously three times weekly for 24 weeks.
b Patients were given PEG-IFN (100mg/week) plus LAM (100mg/day) ormonotherapy PEG-IFN (100mg/week) for 52weeks. Betweenweeks 32 and 52 the dose of PEG-IFN
was reduced to 50mg/week in both treatment groups.
c PEG-IFN 180mg every week for 48 weeks plus placebo once daily; or PEG-IFN 180mg every week for 48weeks plus LAM 100mg daily; or LAM 100mg daily for 48 weeks.
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negativepatients.84GenotypeAwas suggested tobean independent
positive predictor of IFN sustained response (multivariate logistic
regression analysis; p < 0.009).84 Hou et al. (103 HBeAg-positive
chronichepatitisB (CHB)patients;A:46; INNO-LiPAandcloningand
sequencing; follow up 6 months post-treatment) reported that
genotypeA patients have a faster response to IFN compared to those
with other genotypes.85 They reported that the rate of HBeAg
clearance was signiﬁcantly higher in genotype A compared to other
genotypes (including genotype D) after 16 weeks of IFN therapy
(p = 0.014 for A vs. other genotypes; p = 0.05 for A vs. D). Logistic
regressionanalysis revealed thatgenotypeA isapositivepredictorof
IFN responsiveness (16 weeks of treatment; p = 0.001).85 However,
response to IFN therapywas independent of genotype in the case of
prolonged therapy in this study.85
The better responsiveness of genotypes A and B to IFN
compared to D and C may be partially due to the faster
development of mutations in the basal core promoter region in
genotypes D and C than in A and B.23
3.2.3. Inﬂuence of HBV genotypes on PEG-IFN response
The response to PEG-IFN has been reported to be inﬂuenced by
HBVgenotypes inmany studies. Janssenet al. (Table5) reported that
HBeAg loss as a response to PEG-IFN monotherapy or PEG-IFN plus
LAM was inﬂuenced by HBV genotype and that genotypes A and B
had a better response compared to C and D after 52 weeks of
treatment.86 Genotype A patients were signiﬁcantly more respon-sive thanDor C patients and genotype B patientswere slightlymore
responsive than C.86 Flink et al. (n = 266; 52 weeks of treatment;
follow up period 26 weeks; INNO-LiPA) reported that HBeAg-
positive CHBpatients infectedwith genotype A experienced a better
PEG-IFN response (with or without LAM) compared to other
genotypes (loss of HBsAg in A vs. D; p = 0.006).87 Hadziyannis
et al. (n = 448; PEG-IFN plus placebo for 48 weeks) reported that
genotype A patients had higher HBsAg seroconversion in both
HBeAg-positive and negative patients at 24 weeks post-treatment
(HBeAg-positive: A 22%, B 0%, C 2%, D 0%; HBeAg-negative: A 18%, B
2%, C 3%, D 0%).88 In contrast, Lau et al. (271 genotyped patients
treatedwithPEG-IFNplusplacebo for48weeks;A:23;B:76; C: 162;
D: 9; INNO-LiPA) reported no signiﬁcant difference between
different genotypes in HBeAg seroconversion 24 weeks after PEG-
IFN therapy.89 It is important to note that genotype A tended to have
a relatively higher response to PEG-IFN compared to other
genotypes (A 52%, B 30%, C 31%, D 22%).89 It is thus clear that
PEG-IFN should be a ﬁrst-line therapy for genotype A patients.
Another study by Bonino et al. (Table 5) reported that HBeAg
negative patients infected with genotypes B and C responded
better to PEG-IFN compared to genotype D.90
3.2.4. Inﬂuence of HBV genotypes on nucleoside/nucleotide response
and resistance
Contradicting studies have been reported on whether HBV
genotypes inﬂuence the responsiveness to nucleoside/nucleotide
analogues.10,12,91 Most recently,Wiegand et al. compiled data from
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nucleoside/nucleotide analogues (LAM, ADV, entecavir, and
telbivudine) is not signiﬁcantly inﬂuenced by HBV genotype.92
Important to mention is that resistance against LAM (measured as
mutations in the YMDD conserved region) appears to emerge
earlier in genotype A patients compared to genotype D patients.12
In summary, HBeAg-positive genotype B patients have been
found to be more responsive to IFN therapy compared to genotype
C patients; and A gives a better response compared to other
genotypes (including D), especially during short-term therapy.
Patients infected with genotype A seem to have a better response
to PEG-IFN compared to those with other genotypes. HBV
genotypes do not seem to inﬂuence response to nucleoside/
nucleotide antiviral therapy. Tables 4 and 5 summarize the clinical
implications and correlation betweenHBV genotypes and response
to IFN therapy.
3.3. Disease chronicity
3.3.1. Prevalence of genotype A in acute and chronic hepatitis patients
Few studies have reported that genotype A is more prevalent in
chronic thanacutedisease.Mayerat et al. (n = 65;A:31;D:28; length
polymorphism analysis and direct cycle sequencing) reported that
genotype A ismore prevalent in chronic infection and genotype D in
acute disease in European countries (p< 0.0001).93 This ﬁnding is
also supported by Rodriguez-Frias et al. (Table 6).94 In contrast,
Kobayashi et al. (Table 6), in a study on a large population (n = 4430),
reported that genotype A is highly prevalent in acute infectionwhile
C is prevalent in chronic infection.95
3.3.2. Prevalence of genotype D in acute and chronic hepatitis patients
Wai et al. (Table 6) supported the ﬁnding of Rodriguez-Frias
et al. 94 that genotype D is more prevalent in acute disease, and
reported a signiﬁcant association between genotype D and acute
liver failure compared to chronic hepatitis.96 In contrast, Zekri et al.
(Table 6) reported that genotype D was signiﬁcantly more
prevalent in chronic active hepatitis than acute hepatitis
(p < 0.05).9 Genotype A was slightly more prevalent in chronicTable 6
Correlation between HBV genotypes and disease chronicity.
Study Patients and methods Study ﬁndings
Imamura et al. 200398  61 AH; 531 CLD
 Method: ELISA and RFLP
 39% of acute forms
were infected with
 31% of acute self li
fulminant hepatitis
genotype B (p=0.0
Wai et al. 200596  530 CHB cases (matched=
75) compared with 25
ALF cases (USA)
 32% and 16% of ALF
with D, respectivel
and HBeAg
 Method: INNO-LiPA
plus sequencing
Rodriguez-Frias
et al. 200694
 A: 192; D: 234  In acute infection:
 Method: RFLP  In chronic HBV infe
 p=0.03
Zekri et al. 20079  n=68 (genotyped Egyptian
pediatric cancer patients;
46 CAH; 22 AH)
 AH: A 9%; B 45.5%;
 Method: multiplex PCR  CAH: A 10.4%; B 16
mixed 14.6%
Zhang et al. 200899  n=294 acute hepatitis B
 Method: multiplex PCR
and sequencing and
phylogenetic analysis
 20/25 (80%) and 5/
who progressed to
with genotypes C2
(p=0.013: C2 vs. B
Kobayashi et al. 200895  n=4430 (Japan; 153 AH;
4277 CH)
 AH: A 28.6%; B 10.
 Method: ELISA  CH: A 3%; B 12.3%;
AH, acute hepatitis; ALF, acute liver failure; AOR, adjusted odds ratio; CAH, chronic activ
CLD, chronic liver disease; ELISA, enzyme-linked immunosorbent assay; HBeAg, hepatitis
fragment length polymorphism.active hepatitis than acute hepatitis.9 The patient population in the
study of Zekri et al., Egyptian pediatric cancer patients, may be a
limiting factor to the reported ﬁndings.
3.3.3. High prevalence of genotype B in acute and genotype C in
chronic hepatitis
Sakai et al. (n = 203; B: 14; RFLP; p < 0.001) and Imamura et al.
(Table 6; n = 592; ELISA; p < 0.001) reported that genotype B is
more prevalent in acute infection.97,98 Imamura et al. reported that
genotype B was linked to more severe acute disease being
signiﬁcantly more prevalent in fulminant disease than acute self
limited hepatitis.98 Zhang et al. (Table 6) reported that C2 was
more prevalent in patients that progressed to chronic infection
compared to B2.99
Other studies have reported no correlation between HBV
genotypes and disease chronicity rates. For example, Krekulova
et al. (n = 45; A: 33; D: 12; sequencing) reported no correlation
between genotypes A and D and disease chronicity.100
It is still unclear whether genotypes A and D aremore prevalent
in acute or chronic hepatitis patients; however, the current
ﬁndings suggest that genotypes B and C are more prevalent in
acute and chronic infections, respectively. More studies with large
homogeneous populations using the same genotypingmethod that
is veriﬁed by sequencing are needed to reach consistent
conclusions regarding the inﬂuence of genotype on disease
chronicity. Tables 4 and 6 summarize the clinical implications
and the inﬂuence of HBV genotypes on disease chronicity.
3.4. HBV transmission
3.4.1. Sexual transmission
Halfon et al. (Table 7) reported that genotype A was associated
with patients infected through sexual contact, while genotype D
through blood transfusion.101 Koedijk et al. (158 genotyped acute
HBV; sequencing and phylogenetic analysis) reported that 52% and
only 15% of genotype A and D patients, respectively, were infected
via homosexual or bisexual contact, while 16% and 42% were
infected via heterosexual contact.102 Thus genotype A appears toConclusions
of hepatitis and 12% of CLD
genotype B (p<0.001)
 Genotype B is more prevalent in
acute forms of hepatitis than CLD
mited hepatitis and 62.5% of
cases were infected with
27)
 Genotype B is more associated with
fulminant hepatitis than acute self
limited hepatitis
and CHB patients were infected
y (p=0.007) after matching race
 Genotype D is more prevalent in
ALF than CHB
genotype A:D ratio =0.40  Genotype D is more associated
with acute infection compared to Action: genotype ratio A:D=0.83
C 13.6%; D 13.6%; mixed 18.2%  D is more prevalent in CAH than
AH (p<0.05)
.7%; C 6.3%; D 47.9%;
25 (20%) of patients
chronic were infected
and B2, respectively
2)
 HBV C2 is an independent factor for
chronicity development as determined
by multivariate analysis (AOR 6.97
(95% CI 1.59–30.63))
3%; C 59.5%  Distribution of genotypes among acute
and chronic groups was signiﬁcantly
different (p<0.001)C 84.5%
e hepatitis; CH, chronic hepatitis; CHB, chronic hepatitis B; CI, conﬁdence interval;
B e antigen; HBV, hepatitis B virus; PCR, polymerase chain reaction; RFLP, restriction
Table 7
Correlation between HBV genotypes and routes of transmission
Study Patients and methods Study ﬁndings Conclusions
Erhardt et al. 200584  n=165 CH (A: 78;B:
6; C: 11 ;D: 66)
 20%, 67%, 55% and 45% of genotypes A, B, C, and D
patients were infected through perinatal route,
respectively
 Genotypes B, C, and D are more
associated with perinatal transmission
than A (p<0.03) Method: sequencing
Lin et al. 2005109  Eight families with
HBsAg-positive mothers
 Transmission from HBsAg-positive mothers (vertical):
the rate of HBsAg positivity in children was 85.7%
 Genotyping with phylogenic analysis
could be used to study intrafamilial
transmission Seven families with
HBsAg-positive fathers
 From HBsAg-positive fathers (horizontal): the rate
was 65.4%
 Method: RFLP  p=0.16 (non-signiﬁcant difference)
Halfon et al. 2006101  n=262 (A:64; D:70 CH)  5%, 3%, 31%, and 5% of genotype A patients were
transmitted through drug use, transfusion, sexual,
and vertical routes, respectively
 Genotype A is associated with
patients infected through sexual
contact (p<0.001), while genotype
D through BT (p<0.001)
 Method: INNO-LiPA
and sequencing
 3%, 23%, 9%, 7%, and 14% of genotype D patients were
transmitted through drug use, transfusion, sexual, vertical,
and transplantation routes, respectively
Inui et al. 2007105  n=118 (Japanese;
116 CH; 2 AH)
 Genotypes found: C 86%; B 9%; D 2.5%; A 1.0%  C was found to be more strongly
associated with mother-to-child
transmission compared to other
genotypes
 Method: sequencing
 97% and 49% of children infected through the vertical
route and by other routes (such as father to child or
through family members excluding fathers and mothers)
were infected with C, respectively
 Genotype C children who were maternally infected
are much greater in number compared to those
with genotypes B, D, or A (p<0.01)
AH, acute hepatitis; BT, blood transfusion; CH, chronic hepatitis; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; RFLP, restriction fragment length polymorphism.
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standing the association between HBV genotypes and route of
transmission is essential since a recent increase in genotype A, for
example, may indicate a recent lack of proper safe sex
practices.101,102
Sa´nchez et al. (n = 67; G:7; sequencing and phylogenetic
analysis) reported a signiﬁcant difference in genotype distribu-
tion between two patient groups, the ﬁrst comprising chronic or
acute hepatitis patients and the other comprising men who have
sex with men (MSM) (p < 0.001).103 Genotype G was only foundTable 8
Correlation between HBV genotypes and transplantation outcomes
Study Patients and methods Study ﬁndings
Devarbhavi
et al. 2002110
 A: 10; C: 6; D: 5 (HBV-related
transplant patients)
 20%, 50%, and 80% of patients
A, C, and D, respectively, develo
transplantation Method: ELISA
 Survival rates for patients inf
and D were 90%, 83%, and 60
 HBV recurrence developed af
9.1 months post-transplantat
genotypes A, C, and D, respec
 90%, 60%, and 50% of patients
and D, respectively, suffered
Ben-Ari et al.
2004112
 n=81 (Israel; subgroupa)  OLT patients: D 96%; A 4%
 Method: RFLP  Stable patients: D 90.3%; A 3
 All patients who suffered rec
infected with genotype D (NS
Girlanda et al.
200462
 15 genotype A, 13 D, 12 A+D  Genotype D patients were fou
genotype A patients (NS in m Method: INNO-LiPA plus
clonal sequencing followed
by phylogenetic analysis
 27%, 54%, and 33% of genotyp
respectively, suffered recurre
to multivariable analysis)b
Lo et al. 2005111  43 LT genotype B; 74 LT
genotype C (Hong Kong)
 In genotype B patients, cumu
and 3 years after transplanta
while in genotype C patients
respectively (p=0.017)
 Method: sequencing and
phylogenetic analysis
 Liver biopsies after viral brea
patients showed no histologi
were negative to immunostai
 7/10 genotype C patients had
including two patients with ﬁ
ACR, acute cellular rejection; ELISA, enzyme linked immunosorbent assay; HBcAg, hepati
transplantation ; NS, non-signiﬁcant; OLT, orthotopic liver transplantation; RFLP, restr
a Subgroup: 50 OLT patients with HBV DNA negative at the time of transplantation;
b The only factor that signiﬁcantly predicted HBV recurrence in this study was HBVin the MSM group, always co-infected with other genotypes A
or H.103
3.4.2. Vertical transmission
The correlation between HBV genotypes and perinatal (vertical;
mother-to-child)transmissionhasalsobeenreported.Guoetal. (RFLP
and sequencing) reported that 3/7 (42.9%), 3/7 (42.9%), and 1/7 (14%)
of the babies infected through vertical transmission were infected
with B, C, and D, respectively.104 Erhardt et al. (Table 7) reported that
genotypes B, C, and D were more associated with perinatalConclusions
infected with genotypes
ped recurrent HBV after
 Genotype D was associated with
higher HBV recurrence and mortality
after transplantation compared to
genotypes A and Cected with genotypes A, C,
%, respectively  Genotype A was associated with
the most rapid HBV recurrence and
a higher ACR compared to genotypes
C and D
ter a mean time of 2.7, 10, and
ion for patients infected with
tively
infected with genotypes A, C,
ACR
 No statistically signiﬁcant
difference exists between genotype
prevalence in patients who
underwent OLT and stable patients
.2%; C 6.5%
urrence after transplantation were
)
r-folds more likely to die than
ultivariate analysis)
 Genotypes A and D do not
signiﬁcantly inﬂuence the
outcome of LTe A, D, and A/D patients,
nce (A vs. D, p=0.14; NS according
lative rates of viral breakthrough 1, 2,
tion were 0%, 0%, and 4%, respectively,
were 12%, 18%, and 21%,
 Genotype C is associated with high
recurrence rates and severe graft
damage due to the emergence of
lamivudine-resistant mutants
kthrough taken from two genotype B
cal evidence of recurrent hepatitis and
ning with HBcAg or HBsAg
histological recurrence,
brosing cholestatic hepatitis
tis B core antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LT, liver
iction fragment length polymorphism.
31 stable patients with anti-HBe positive.
replication at the time of liver transplantation (p=0.03).
B.S.S. Guirgis et al. / International Journal of Infectious Diseases 14 (2010) e941–e953 e951transmission than A.84 Inui et al. (Table 7) also reported a high
association between genotype C and vertical HBV transmission.105
3.4.3. Other routes of transmission
Recently, Panessa et al. (n = 70 acute hepatitis; D: 44;
sequencing and phylogenetic analysis) reported that genotype D
was signiﬁcantly prevalent in injection drug users (p = 0.0025) and
previously incarcerated patients (p = 0.0067).106
It is important to note that the link between genotypes and
certain transmission routes does not mean that they cannot be
transmitted through other routes. Genotypes B and C can be
transmitted sexually and genotype A via vertical transmission.
Genotype E can also be transmitted through sexual and vertical
routes.84,99,101,107,108
In summary, genotype A seems to be linked to bisexual or
homosexual contact, genotype G to homosexual (MSM), and D to
heterosexual. Genotypes B, C, and probably D have been found to
be associatedwith vertical transmission. Tables 4 and 7 summarize
the clinical implications and the correlation between HBV
genotypes and modes of transmission.
Genotyping together with phylogenetic analysis may also allow
a better understanding and tracing of intrafamilial transmission.
Lin et al. (Table 7) reported that children infected through close
contact with infected fathers had a comparable HBsAg positivity to
those infected through vertical transmission.109 This illustrates the
high possibility of horizontal transmission between HBsAg-
positive fathers and their children, underscoring the importance
of child vaccination.
3.5. Liver transplantation
A few studies with conﬂicting results have been published
regarding the correlation between HBV genotypes and transplanta-
tion outcomes. Devarbhavi et al. (Table 8) reported that genotypeD is
associatedwith higherHBV recurrence andmortality after transplan-
tation compared to genotypes A and C.110 Genotype Awas associated
with the most rapid HBV recurrence rate and a higher acute cellular
rejection rate compared to genotypes C and D.110 Lo et al. (Table 8)
reported that genotype C was associated with higher recurrence and
more severe graft damage compared to genotype B.111
In contrast, other studies have concluded that HBV genotypes
do not inﬂuence the need for transplantation nor its outcome. Ben-
Ari et al. (Table 8) reported no statistically signiﬁcant difference in
genotype prevalence in patients undergoing liver transplantation
and stable patients.112 Girlanda et al. (Table 8) reported that
genotypes A and D were not signiﬁcant predictors of transplanta-
tion outcomes.61 Tables 4 and 8 summarize the clinical implica-
tions and correlation between HBV genotypes and liver
transplantation outcomes.
3.6. Occult HBV
Occult HBV infection is a special form of hepatitis B infection
where patients are negative for HBsAg, while at the same time
being positive for HBV DNA. Over the past few years, few studies
have investigated the association between HBV genotypes and
occult infection. Raffa et al. (n = 18 occult HBV genotyped patients;
sequencing) reported that genotypes A and D are highly prevalent
in occult HBV infection in HIV patients.113 Pinarbasi et al. (n = 13;
occult HBV patients) reported that all HBV occult patients were
infected with genotype D.114
4. Conclusions
At least 10 HBV genotyping techniques currently exist, of which
sequencing is still considered the gold standard method. INNO-LiPA may be a suitable alternative, but it is expensive compared to
other methods such as multiplex PCR, RFLP, and serotyping. Other
genotyping techniques have been developed including oligonucle-
otide microarray chips, reverse dot blot, RFMP, invader assay, and
real-time PCR, and have been found to be highly sensitive.
Numerous studies have investigated the inﬂuence of HBV
genotypes on clinical outcomes. Genotype C is associated with
rapid ﬁbrosis development, high HCC development rate, recur-
rence, and metastasis compared to genotype B. It appears that
genotype Dmay be associated with more severe disease compared
to A and that genotype F is linked to highmortality rates. Although
HBV genotypes do not signiﬁcantly inﬂuence response to nucleo-
side/nucleotide antiviral therapy, responsiveness to IFN is clearly
affected by genotype. HBeAg-positive patients infected with
genotype B have a better response compared to those with
genotype C, and genotype A responds better than genotype D,
especially during short term therapy. Genotype A also responds
well to PEG-IFN.
It is still unclear whether genotypes A and D aremore prevalent
in acute or chronic hepatitis, however genotypes B and C appear to
be more prevalent in acute and chronic infection, respectively.
Genotype A appears to be linked to bisexual or homosexual
contact, genotype G to homosexual (MSM), and D to heterosexual.
Genotypes B, C, and probably D are linked to vertical transmission.
Very few studies have reported the inﬂuence of HBV genotypes on
transplantation outcome and occult HBV infection. Studies
showing the inﬂuence of genotypes E–H and HBV subgenotypes
on clinical outcomes are scarce.
The Asian-Paciﬁc Association for the Study of the Liver (APASL),
European Association for the Study of the Liver (EASL), and
American Association for the Study of Liver Diseases (AASLD)
guidelines have recommended further studies on the correlation
between HBV genotypes and clinical outcomes before using HBV
genotyping as a routine test in diseasemanagement.115–117 Studies
using large well-characterized patient populations that implement
a sensitive genotyping technique veriﬁed by sequencing are clearly
needed to support existing evidence and resolve contradictory
ﬁndings.
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